Abstract：ObjectiveTo investigate the clinical effect of Febuxostat in the treatment of gout combined with hyperlipidemia.MethodsFrom August 2015 to March 2017,clinical data from 88 gout patients with hyperlipidemia treated in our hospital were selected as objects.They were evenly divided into two groups based on odd or even number,44 cases in each group.In control group Allopurinol was used,while in experimental group Febuxostat was adopted.The levels of blood lipid and blood uric acid,the occurrence of gout and incidence of adverse reactions in the two groups were compared and observed.ResultsBefore treatment,there was no significant difference in blood lipid level or blood uric acid between the two groups(P＞0.05).After therapy,the two indicators mentioned above in the experimental group were lower than those in the control group,the differences were statistically significant(P＜0.05).The incidence of gout and adverse reactions in both groups were compared,the differences were not statistically significant(P＞0.05).ConclusionCompared with Allopurinol,application of Febuxostat in the treatment of gout patients with hyperlipidemia,though similar incidence of adverse reations by the two methods,the effect to decrease the blood lipid level is more remarkable,which can decrease the levels of triglycerides,low-density lipoprotein,and serum total cholesterol.
Wells AF，Mac Donald PA，Chefo S，et al.African American patients with gout：efficacy and safety of febuxostat vs allopurinol[J].BMC musculoskeletal disorders，2012，13（1）：1.
京公网安备 11010502046607号